Bradmer Pharmaceuticals Inc. (TSE:GLX – Free Report) – Equities researchers at Atb Cap Markets reduced their FY2024 EPS estimates for Bradmer Pharmaceuticals in a research report issued on Sunday, January 26th. Atb Cap Markets analyst M. Toner now forecasts that the company will post earnings of $3.01 per share for the year, down from their prior forecast of $3.63. Atb Cap Markets also issued estimates for Bradmer Pharmaceuticals’ FY2025 earnings at $1.51 EPS.
Bradmer Pharmaceuticals (TSE:GLX – Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported C($0.18) earnings per share for the quarter, beating the consensus estimate of C($0.52) by C$0.34.
Bradmer Pharmaceuticals Price Performance
Read More
- Five stocks we like better than Bradmer Pharmaceuticals
- Using the MarketBeat Stock Split Calculator
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- Canadian Penny Stocks: Can They Make You Rich?
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- Low PE Growth Stocks: Unlocking Investment Opportunities
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.